SOPHiA DDM™ for Oncology
Reveal what matters most
Everyone touched by cancer needs a clear path to the right care.
We simplify complex data and reveal what matters most.
Genomic-powered precision medicine is at the forefront of innovation in cancer research. Advancements in next-generation sequencing (NGS) technology has brought about a new era of cancer care, furthering our understanding of disease mechanisms and therapeutic targets. However, with increasingly large and complex NGS data sets and multiple biomarkers, efficient and precise detection of relevant genomic alterations can be challenging.
The SOPHiA DDM™ Platform removes the complexity from genomic analysis. Our algorithm-enabled bundle solutions empower data-driven decisions at all stages of the cancer care journey through a combination of accurate healthcare data analysis, intuitive interpretation functionalities, and secure knowledge sharing.
From confident analysis to relevant insights
SOPHiA DDM™ offers a streamlined workflow to annotate, interpret and report relevant NGS variants, minimizing complexity, thus increasing efficiency of your decision-making process.
Knowledge at your fingertips
A decade of cumulative health data has been effectively analyzed in the SOPHiA DDM™ Platform, allowing us to leverage collective intelligence, machine learning, and pattern recognition to develop a breadth of solutions with finely tuned accuracy.
Solid Tumours
Blood Cancers
Hereditary Cancers
Our featured technology
Genomic Integrity Index
Our deep learning algorithm leverages low-pass whole genome sequencing data to reveal the extent of genomic scarring caused by homologous recombination deficiency (HRD).
RNAtarget Technology
An advanced customizable RNA-based sequencing approach that offers a single workflow with confident novel fusion detection, while also providing ability to detect SNVs/Indels and expression changes.
SOPHiA DDM™ for CGP
SOPHiA DDM™ combines analytical performance with streamlined interpretation of complex genomic variants, (including SNVs, Indels, CNVs, fusions, MSI and TMB), in the context of comprehensive genomic profiling (CGP).
Our impact beyond genomics
Radiomics
SOPHiA DDM™ for Radiomics offers imaging, end-to-end analytical solutions to help discover new biomarkers for disease evolution monitoring, treatment efficacy evaluation and therapeutic outcomes prediction.
Multimodality
To further advance precision medicine, we are pioneering the synergistic combination of radiomics, genomics and biological data. From biomarker discovery to patient stratification, we believe a multimodal approach holds a revolutionary potential for the future of precision medicine.
Want to know more?
Get in touch with us.